查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371914

到 2030 年生物标记测试服务市场预测：按测试类型、技术、应用、最终用户和地区进行的全球分析

Biomarker Testing Services Market Forecasts to 2030 - Global Analysis By Testing Type, By Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球生物标记检测服务市场规模为 9.082 亿美元，预计预测期内年复合成长率为 8.9%，到 2030 年将达到 1.6619 亿美元。

一种测试程序，用于搜寻组织、血液或其他体液样本中的特定基因、蛋白质或其他可能是某种疾病或疾病（例如癌症）迹象的物质。此外，生物标记测试有时用于寻找可能增加癌症或其他疾病风险的染色体或遗传异常。生物标记测试以及切片检查等其他程序可以帮助诊断某些癌症。

根据 ClinicalTrials.gov 统计，2018 年註册试验超过 262,298 项，截至 2022 年 9 月，註册试验超过 399,518 项。随着临床研究经费的增加，临床试验预计在未来几年将会改善。预计这将增加对药物研发研究的需求，从而增加疫情后时代对生物标记测试的需求。

慢性病发生率增加和技术进步

随着糖尿病、心血管疾病和癌症等慢性病的罹患率增加，对生物标记检测服务的需求也增加。生物标记对于这些疾病的早期检测、诊断和监测极为重要。此外，技术的发展彻底改变了生物标记测试领域。质谱、次世代定序、高通量筛选方法和免疫分析都在提高生物标记分析的精确度和有效性。由于这些发现和技术进步，预计市场在预测期内将实现盈利增长。

与调查相关的高成本

全球生物标记研究服务市场的快速扩张可能会受到生物技术和製药公司无法进行生物标记研究以及开发新药所需的研究成本高昂的限制。此外，成本效益低、样本采集和储存方面的技术挑战以及法规和报销框架不足是未来年度全球生物标记研究服务市场开拓的潜在障碍，但这是可能的。

加大研发投入

推动市场扩张的关键因素包括药物研发投资的增加、癌症治疗中对精准医疗的需求不断增加以及感染疾病和慢性病负担的增加刺激了对生物标誌物检测的需求。此外，过去年度来，临床试验的数量稳定增加。根据 ClinicalTrials.gov 统计，2018 年註册试验超过 262,298 项，截至 2022 年 9 月，註册试验超过 399,518 项。随着临床研究资金的增加，临床试验预计在未来几年会变得更好。在大流行后时代，对药物研发研究和最终生物标记测试的需求预计将会增加。

缺乏熟练的专业人员

由于医疗保健部门缺乏合格且经验丰富的专业人员，全球生物分析测试服务市场的扩张受到阻碍。测试程序使用最尖端科技和采样，因此合格的医务人员对于药物开发和测试都至关重要。为了进行测试，实验室和研究设施需要经过训练的人员。否则，缺乏合格人员可能会带来健康风险并降低技术采用率。这些因素共同限制了市场的扩张。

COVID-19 的影响：

COVID-19 大流行对生物标记测试服务市场产生了重大影响。在最初因医疗设施关闭和就诊人数减少而受到干扰后，随着诊断测试、血清学测试和疫苗功效研究变得更加重要，对生物标记测试的需求激增。生物标记测试在识别和监测 COVID-19 病例、推进治疗方法和疫苗研究以及评估其有效性方面发挥了至关重要的作用。这次疫情加速了这一领域的创新，促进了新型生物标记和诊断技术的发展。大流行之后，市场继续增长，因为医疗保健系统优先考虑早期疾病检测和个人化医疗，凸显了生物标记测试服务的重要性。

生物製药和製药公司部门预计将在预测期内成为最大的部门

预计製药和生物技术公司领域将在预测期内占据最大的市场占有率。推动该领域成长的主要因素之一是製药和生物技术产业为临床研究提供的资金不断增加。这就是Astra Zeneca和罗氏于 2022 年 9 月联手重塑中东和北非癌症诊断和治疗的原因。此外，製药公司对开发标靶癌症疗法的兴趣日益浓厚，这也促进了该领域的成长。

血清学免疫抗原性/中和抗体片段预计在预测期内出现最高的年复合成长率

在预测期内，血清免疫抗原性和中和抗体领域预计将出现良好的成长。需要这些测试来评估临床前模型中的免疫反应，使用临床样本来寻找响应治疗而产生的抗体。它提高了疫苗和生技药品製造流程的可靠性，同时能够评估功效和安全性。在单株抗体 (mAb) 开发的临床阶段，越来越多地使用基于血清学、免疫抗原性和中和抗体的测试，以确保反应不会威胁患者安全。这推动了该领域生物分析测试的需求。

占比最大的地区：

预计北美将在预测期内主导市场。该地区存在提供生物标记测试服务的主要市场参与者，这是支持该地区市场的因素之一。此外，复杂的医疗基础设施的存在、疾病负担的增加导致实验室诊断测试数量的增加以及公共机构研发投资的增加正在推动该地区的市场扩张。

复合年复合成长率最高的地区：

由于製药和生物技术研发业务的资金增加，预计欧洲地区在预测期内将快速成长。心血管疾病的增加也是推动欧洲市场的因素。此外，糖尿病是该地区的一个主要问题。过去年度来，该地区一些国家的糖尿病发生率显着增加，有时增加超过 50%。因此，所有这些因素预计将在预测期内推动市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球生物标记测试服务市场：依测试类型

  • 生物标记测试
  • 基于细胞的检测
  • 方法开发最佳化和检验
  • 药物动力学研究
  • 血清学免疫抗原性和中和抗体
  • 毒理学服务
  • 病毒测试
  • 其他类型的测试

第6章全球生物标记测试服务市场：依技术分类

  • 质谱
  • 色谱法

第7章全球生物标记测试服务市场：依应用分类

  • 神经病学
  • 心臟病学
  • 消化内科
  • 血液学
  • 免疫学
  • 感染疾病
  • 代谢紊乱
  • 肿瘤学
  • 整形外科
  • 其他用途

第8章全球生物标记测试服务市场：依最终用户分类

  • 生物製药和製药公司
  • 合约开发/製造组织
  • 受託研究机构
  • 医疗机构
  • 其他最终用户

第9章全球生物标记测试服务市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Euro fins Scientific
  • Abbott Laboratories
  • Bio Agilytix Labs
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories
  • Epigenetics AG
  • F. Hoffmann-La Roche Ltd.
  • ICON Plc
  • Intertek Group Plc
  • IQVIA
  • Johnson & Johnson Services, Inc.
  • Labcorp Drug Development
  • Qiagen
  • SGS SA
  • Siemens Healthineers AG
  • Syneos Health
  • Thermo Fisher Scientific, Inc.
Product Code: SMRC23971

According to Stratistics MRC, the Global Biomarker Testing Services Market is accounted for $900.82 million in 2023 and is expected to reach $1636.19 million by 2030 growing at a CAGR of 8.9% during the forecast period. A laboratory procedure that looks for specific genes, proteins, or other substances that may be a symptom of a disease or illness, such as cancer, in a sample of tissue, blood, or other bodily fluid. Additionally, biomarker testing can be used to check for chromosomal or gene anomalies that may increase a person's risk of developing cancer or other diseases. The use of biomarker testing in conjunction with other procedures, like biopsies, can help diagnose some cancers.

According to ClinicalTrials.gov, more than 262,298 studies were registered in 2018, while more than 399,518 trials were registered as of September 2022. Clinical trials are projected to improve in the future years as clinical research funding increases. This is predicted to increase demand for drug discovery research and, as a result, demand for biomarker testing in the post-pandemic era.

Market Dynamics:

Driver:

Increasing incidence of chronic illnesses and technological advancements

The demand for biomarker testing services is rising as the prevalence of chronic diseases like diabetes, cardiovascular disease, and cancer rises. In the early detection, diagnosis, and monitoring of these diseases, biomarkers are extremely important. In addition, technological developments have transformed the field of biomarker testing. Mass spectrometry, next-generation sequencing, high-throughput screening methods, and immunoassays have all improved the precision and effectiveness of biomarker analysis. As a result of these discoveries and technological advancements, the market is predicted to grow profitably during the forecast period.

Restraint:

High cost associated with research

The rapidly expanding global market for biomarker research services may be constrained by biotechnology and pharmaceutical companies' inability to conduct biomarker research and by the high cost of conducting the research required for the development of new drugs. Moreover, low cost-to-benefit ratios, technical challenges with sample collection and storage, and inadequate regulatory and reimbursement frameworks are additional potential roadblocks that may hinder the development of the global market for biomarker research services in the years to come.

Opportunity:

Growing investment in R&D

Some of the key factors propelling market expansion include increasing investments in pharmaceutical R&D, the growing demand for precision medicine used in cancer therapy, and an increase in the burden of infectious and chronic diseases fueling demand for biomarker testing. Furthermore, over the previous five years, the number of clinical trials has been steadily rising. ClinicalTrials.gov reports that more than 262,298 studies were registered in 2018 and that, as of September 2022, there were more than 399,518 trials registered. Clinical trials are expected to get better in the coming years as funding for clinical research rises. In the post-pandemic era, it is anticipated that this will lead to a rise in demand for drug discovery research and, consequently, for biomarker testing.

Threat:

Lack of skilled professionals

The expansion of the global market for bioanalytical testing services is being hampered by a lack of qualified or experienced professionals in the healthcare sector. Due to the use of cutting-edge technologies and sampling in testing procedures, qualified medical personnel are essential for both drug development and testing. In order to conduct the tests, laboratories and research facilities need trained personnel; otherwise, a lack of qualified staff may result in health risks, which would lower the technology's adoption rate. These factors limit market expansion as a whole.

COVID-19 Impact:

The COVID-19 pandemic has significantly impacted the biomarker testing services market. While there was an initial disruption due to lockdowns and reduced healthcare visits, the demand for biomarker testing surged as diagnostic tests, serology tests, and vaccine efficacy studies became critical. Biomarker testing played a pivotal role in identifying and monitoring COVID-19 cases, driving research for therapies and vaccines, and assessing their effectiveness. The pandemic accelerated innovation in the field, leading to the development of novel biomarkers and diagnostic technologies. Post-pandemic, the market continues to grow as healthcare systems prioritize early disease detection and personalized medicine, underscoring the importance of biomarker testing services.

The biopharmaceutical and pharmaceutical companies segment is expected to be the largest during the forecast period

During the forecast period, the pharmaceutical and biotechnology companies segment is anticipated to have the largest market share. One of the main factors driving the segment's growth is an increase in the funding provided by the pharmaceutical and biotechnology industries for clinical research. Due to this, AstraZeneca and Roche partnered in September 2022 to reimagine cancer diagnosis and treatment in the Middle East and North Africa. Additionally, pharmaceutical companies are becoming more interested in creating targeted cancer therapies, which is contributing to segment growth.

The serology immunogenicity and neutralizing antibodies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the serology immunogenicity and neutralizing antibodies segment is anticipated to have lucrative growth. To find antibodies produced against a treatment, these tests are required for assessing the immune response in preclinical models using clinical samples. It increases the dependability of the production process for vaccines and biologics while enabling the organization to assess efficacy and safety. The growing use of serology, immunogenicity, and neutralizing antibody-based testing during the clinical phase for the development of monoclonal antibodies (mAbs) to ensure that the response does not jeopardize patient safety is driving up demand for bioanalytical testing in this segment.

Region with largest share:

During the period of the forecast, North America is anticipated to dominate the market. Major market players who provide services for biomarker testing are present in the region, which is one of the factors supporting the market in the area. Additionally, the presence of sophisticated healthcare infrastructure, the rise in disease burden that leads to an increase in laboratory diagnostic testing, and growing R&D investment by public organizations in the region are driving market expansion in this region.

Region with highest CAGR:

Owing to increasing funding for pharmaceutical and biotechnology R&D operations, the Europe region is expected to grow quickly over the forecast period. The rise in cardiovascular disease is another factor driving the market in Europe. Additionally, diabetes is a major problem in this region. It has increased significantly in several countries in the region over the past ten years, sometimes by more than 50%. All of these factors are therefore anticipated to boost market growth during the forecast period.

Key players in the market:

Some of the key players in Biomarker Testing Services Market include: Euro fins Scientific, Abbott Laboratories, Bio Agilytix Labs, Bio-Rad Laboratories, Inc., Charles River Laboratories, Epigenetics AG, F. Hoffmann-La Roche Ltd., ICON Plc, Intertek Group Plc, IQVIA, Johnson & Johnson Services, Inc., Labcorp Drug Development, Qiagen, SGS SA, Siemens Healthineers AG, Syneos Health and Thermo Fisher Scientific, Inc.

Key Developments:

In September 2023, QIAGEN announced the expansion of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), to include artificial intelligence (AI)-enhanced coverage of thousands of rare disease genes, advancing its AI-capabilities that have been established for over two decades. The expansion complements the human-certified content curation of QCI Interpret and enables complete bibliographical coverage of the clinical exome.

In July 2023, Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease (AD). The LucentAD test, which will be available to healthcare providers as an aid in conjunction with other diagnostic tools, provides clinicians with a simplified process to quickly assess the likelihood of a patient having amyloid pathology consistent with AD. This information will help healthcare providers determine appropriate follow up and treatment planning for a suspected Alzheimer's patient.

In June 2023, JennyCo, Inc., a first-of-its-kind healthcare data exchange powered by Web3, has announced that it has partnered with AYUMETRIX, a leading provider of laboratory testing services.

Testing Types Covered:

  • Biomarker Testing
  • Cell-based Assays
  • Method Development Optimization and Validation
  • Pharmacokinetic Testing
  • Serology Immunogenicity and Neutralizing Antibodies
  • Toxicology Services
  • Virology Testing
  • Other Testing Types

Technologies Covered:

  • Mass Spectrometry
  • Chromatography

Applications Covered:

  • Neurology
  • Cardiology
  • Gastroenterology
  • Hematology
  • Immunology
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology
  • Orthopedics
  • Other Applications

End Users Covered:

  • Biopharmaceutical and Pharmaceutical Companies
  • Contract Development and Manufacturing Organizations
  • Contract Research Organizations
  • Healthcare Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biomarker Testing Services Market, By Testing Type

  • 5.1 Introduction
  • 5.2 Biomarker Testing
  • 5.3 Cell-based Assays
  • 5.4 Method Development Optimization and Validation
  • 5.5 Pharmacokinetic Testing
  • 5.6 Serology Immunogenicity and Neutralizing Antibodies
  • 5.7 Toxicology Services
  • 5.8 Virology Testing
  • 5.9 Other Testing Types

6 Global Biomarker Testing Services Market, By Technology

  • 6.1 Introduction
  • 6.2 Mass Spectrometry
  • 6.3 Chromatography

7 Global Biomarker Testing Services Market, By Application

  • 7.1 Introduction
  • 7.2 Neurology
  • 7.3 Cardiology
  • 7.4 Gastroenterology
  • 7.5 Hematology
  • 7.6 Immunology
  • 7.7 Infectious Diseases
  • 7.8 Metabolic Disorders
  • 7.9 Oncology
  • 7.10 Orthopedics
  • 7.11 Other Applications

8 Global Biomarker Testing Services Market, By End User

  • 8.1 Introduction
  • 8.2 Biopharmaceutical and Pharmaceutical Companies
  • 8.3 Contract Development and Manufacturing Organizations
  • 8.4 Contract Research Organizations
  • 8.5 Healthcare Institutes
  • 8.6 Other End Users

9 Global Biomarker Testing Services Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Euro fins Scientific
  • 11.2 Abbott Laboratories
  • 11.3 Bio Agilytix Labs
  • 11.4 Bio-Rad Laboratories, Inc.
  • 11.5 Charles River Laboratories
  • 11.6 Epigenetics AG
  • 11.7 F. Hoffmann-La Roche Ltd.
  • 11.8 ICON Plc
  • 11.9 Intertek Group Plc
  • 11.10 IQVIA
  • 11.11 Johnson & Johnson Services, Inc.
  • 11.12 Labcorp Drug Development
  • 11.13 Qiagen
  • 11.14 SGS SA
  • 11.15 Siemens Healthineers AG
  • 11.16 Syneos Health
  • 11.17 Thermo Fisher Scientific, Inc.

List of Tables

  • 1 Global Biomarker Testing Services Market Outlook, By Region (2021-2030) ($MN)
  • 2 Global Biomarker Testing Services Market Outlook, By Testing Type (2021-2030) ($MN)
  • 3 Global Biomarker Testing Services Market Outlook, By Biomarker Testing (2021-2030) ($MN)
  • 4 Global Biomarker Testing Services Market Outlook, By Cell-based Assays (2021-2030) ($MN)
  • 5 Global Biomarker Testing Services Market Outlook, By Method Development Optimization and Validation (2021-2030) ($MN)
  • 6 Global Biomarker Testing Services Market Outlook, By Pharmacokinetic Testing (2021-2030) ($MN)
  • 7 Global Biomarker Testing Services Market Outlook, By Serology Immunogenicity and Neutralizing Antibodies (2021-2030) ($MN)
  • 8 Global Biomarker Testing Services Market Outlook, By Toxicology Services (2021-2030) ($MN)
  • 9 Global Biomarker Testing Services Market Outlook, By Virology Testing (2021-2030) ($MN)
  • 10 Global Biomarker Testing Services Market Outlook, By Other Testing Types (2021-2030) ($MN)
  • 11 Global Biomarker Testing Services Market Outlook, By Technology (2021-2030) ($MN)
  • 12 Global Biomarker Testing Services Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • 13 Global Biomarker Testing Services Market Outlook, By Chromatography (2021-2030) ($MN)
  • 14 Global Biomarker Testing Services Market Outlook, By Application (2021-2030) ($MN)
  • 15 Global Biomarker Testing Services Market Outlook, By Neurology (2021-2030) ($MN)
  • 16 Global Biomarker Testing Services Market Outlook, By Cardiology (2021-2030) ($MN)
  • 17 Global Biomarker Testing Services Market Outlook, By Gastroenterology (2021-2030) ($MN)
  • 18 Global Biomarker Testing Services Market Outlook, By Hematology (2021-2030) ($MN)
  • 19 Global Biomarker Testing Services Market Outlook, By Immunology (2021-2030) ($MN)
  • 20 Global Biomarker Testing Services Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • 21 Global Biomarker Testing Services Market Outlook, By Metabolic Disorders (2021-2030) ($MN)
  • 22 Global Biomarker Testing Services Market Outlook, By Oncology (2021-2030) ($MN)
  • 23 Global Biomarker Testing Services Market Outlook, By Orthopedics (2021-2030) ($MN)
  • 24 Global Biomarker Testing Services Market Outlook, By Other Applications (2021-2030) ($MN)
  • 25 Global Biomarker Testing Services Market Outlook, By End User (2021-2030) ($MN)
  • 26 Global Biomarker Testing Services Market Outlook, By Biopharmaceutical and Pharmaceutical Companies (2021-2030) ($MN)
  • 27 Global Biomarker Testing Services Market Outlook, By Contract Development and Manufacturing Organizations (2021-2030) ($MN)
  • 28 Global Biomarker Testing Services Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • 29 Global Biomarker Testing Services Market Outlook, By Healthcare Institutes (2021-2030) ($MN)
  • 30 Global Biomarker Testing Services Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.